- /
- Supported exchanges
- / US
- / RHHVF.OTCQX
Roche Holding AG Participation (RHHVF OTCQX) stock market data APIs
Roche Holding AG Participation Financial Data Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Roche Holding AG Participation (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Roche Holding AG Participation data using free add-ons & libraries
Get Roche Holding AG Participation Fundamental Data
Roche Holding AG Participation Fundamental data includes:
- Net Revenue: 63 488 M
- EBITDA: 23 429 M
- Earnings Per Share: 14
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-23
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding AG Participation News
New
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash positio...
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis, Inc. EXEL reported better-than-expected results for the third quarter of 2025. Adjusted earnings of 78 cents per share beat the Zacks Consensus Estimate of 68 cents. The company registered ...
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
Corcept Therapeutics CORT reported third-quarter 2025 earnings of 16 cents per share, which missed the Zacks Consensus Estimate of 18 cents. The company had reported earnings of 41 cents per share in ...
CNS Summit releases annual Digital Innovation Index
BOSTON, Nov. 5, 2025 /PRNewswire/ -- The CNS Summit Digital Innovation Index, created in partnership with IDEA Pharma, a division of SAI Med Partners, was unveiled during the CNS Summit annual meeting...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.